Lantheus (NASDAQ:LNTH) Earns "Buy" Rating from Truist Financial

Truist Financial reissued their buy rating on shares of Lantheus (NASDAQ:LNTH - Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $120.00 price target on the medical equipment provider's stock, down from their previous price target of $135.00.

LNTH has been the subject of a number of other reports. JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research report on Thursday. Redburn Atlantic assumed coverage on Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. B. Riley boosted their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Finally, Leerink Partners raised their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $122.50.

Lantheus Stock Down 0.9 %

NASDAQ:LNTH traded down $0.81 during trading hours on Friday, hitting $87.50. 1,618,137 shares of the company traded hands, compared to its average volume of 993,186. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The company has a market cap of $6.08 billion, a PE ratio of 14.66 and a beta of 0.51. The firm's 50-day simple moving average is $107.71 and its 200-day simple moving average is $95.52. Lantheus has a one year low of $50.20 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $378.73 million for the quarter, compared to analyst estimates of $373.58 million. Equities analysts predict that Lantheus will post 5.99 earnings per share for the current year.

Insider Activity

In related news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company's stock, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 2.10% of the company's stock.

Institutional Investors Weigh In On Lantheus

Several hedge funds have recently added to or reduced their stakes in LNTH. GAMMA Investing LLC lifted its position in Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after buying an additional 208 shares during the last quarter. Signaturefd LLC raised its stake in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 92 shares in the last quarter. Nkcfo LLC purchased a new stake in shares of Lantheus in the 2nd quarter valued at $47,000. UMB Bank n.a. grew its holdings in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. purchased a new position in Lantheus in the 3rd quarter worth $51,000. Institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.